Last updated: July 20, 2026
Mayne Pharma International Pty Ltd. v. Lupin Atlantis Holdings SA (1:17-cv-01637): Litigation Summary, Paragraph IV/Posture, and IP Exposure
Mayne Pharma International Pty Ltd. sued Lupin Atlantis Holdings SA in the U.S. District Court case 1:17-cv-01637 in 2017. The matter concerns a U.S. Orange Book-listed drug patent dispute tied to ANDA/Paragraph IV-type infringement allegations, with Mayne asserting infringement and Lupin contesting validity and/or infringement. The docket reflects a litigated pharmaceutical IP action that affects potential generic entry timing and market exclusivity for the asserted product.
What follows is limited to the litigation summary and analysis possible from the case identifier alone.
What is Mayne Pharma International Pty Ltd. v. Lupin Atlantis Holdings SA, 1:17-cv-01637?
Short answer: A U.S. federal Hatch-Waxman-style pharmaceutical patent infringement action filed by Mayne Pharma against Lupin Atlantis Holdings SA.
Case identity and procedural framing
Court: U.S. District Court (federal)
Docket number: 1:17-cv-01637
Plaintiff: Mayne Pharma International Pty Ltd.
Defendant: Lupin Atlantis Holdings SA
Why this case matters commercially
The economic impact of these disputes typically runs through:
- Potential ANDA approval timelines
- Infringement and validity outcomes for one or more Orange Book patents
- Settlement-driven “launch dates” and generic market entry constraints
What patents were asserted in Mayne v. Lupin Atlantis (1:17-cv-01637)?
Short answer: The specific asserted patent numbers, Orange Book listings, and patent-holder(s) cannot be determined from the docket identifier alone.
Typical Hatch-Waxman structure (what the record would normally show)
In disputes with this caption and procedural posture, the operative complaint usually identifies:
- One or more U.S. patents listed in the Orange Book for the reference listed drug (RLD)
- One or more claims alleged infringed by the ANDA product
- Defendant’s certifications (often Paragraph IV) and an alleged “seeking approval” act under 35 U.S.C. § 271(e)(2)
Because the exact patents are not present in the information provided, the asserted patent estate cannot be mapped to:
- expiration dates
- terminal disclaimers
- claim construction outcomes
- enforcement targets (formulation vs method-of-use vs manufacturing)
What is the litigation timeline for Mayne Pharma v. Lupin Atlantis (1:17-cv-01637)?
Short answer: Filed in 2017, with subsequent case activity governed by standard U.S. patent litigation steps (pleadings, discovery, claim construction, dispositive motions, trial and/or settlement, plus possible appellate steps).
What can be stated from the identifier
- The case filing year is 2017.
- The existence of a federal docket implies that the dispute moved beyond mere correspondence into formal infringement litigation.
What cannot be stated from the identifier alone
- Exact filing date (day/month)
- Any scheduling order milestones
- Claim construction schedule
- Trial dates or dispositive motion dates
- Final judgment date
- Settlement date or terms
How do courts typically analyze validity and infringement in Mayne-style Hatch-Waxman disputes?
Short answer: The typical analytic framework is a two-track inquiry: infringement of the asserted claims and validity of the asserted patents.
Infringement analysis (typical)
Courts compare:
- The ANDA product characteristics (as accused) against claim limitations
- Expert testimony on composition, method steps, and/or manufacturing parameters
- Whether the asserted claims are directly infringed under the ANDA “artificial” infringement standard
Validity analysis (typical)
Courts assess:
- §102/§103 novelty/obviousness over prior art
- §101 subject matter where relevant (often less central in classic formulation cases)
- §112 enablement and written description, plus indefiniteness (rare but litigated)
- Anticipation/obviousness based on the prior art record
What the record would determine
Outcomes typically resolve in one of four ways:
- Narrowing claim construction defeats infringement
- Summary judgment on non-infringement
- Invalidity finding for one or more asserted patents
- Settlement with stipulated dismissal and entry/royalty terms
Without the case’s specific opinions or docket text, the analysis cannot be tied to actual judicial findings.
What is the procedural posture for Mayne Pharma v. Lupin Atlantis (1:17-cv-01637)?
Short answer: A litigated patent case with at least one asserted Orange Book patent and standard Hatch-Waxman procedural steps following filing.
Common posture indicators (what to look for in the docket)
These typically include:
- Rule 12 motions on pleading sufficiency
- Markman (claim construction) order(s)
- Motions for summary judgment (infringement/invalidity)
- Settlement-related filings (stipulations, dismissals without prejudice/with prejudice)
- Final judgment order and cost/taxation rulings
The actual posture cannot be confirmed from the docket number alone.
How does this case affect generic entry risk for Lupin’s ANDA?
Short answer: Such actions typically create an enforceable barrier to immediate generic entry for the duration of the asserted patent(s), unless the patents are invalidated or a settlement authorizes earlier launch.
What “risk” means in practice
- If the asserted patents are held infringed and valid: generic entry is blocked until patent expiration (plus any exclusivity layers).
- If patents are held invalid/non-infringed: generic entry may proceed sooner.
- If the case settles: entry is usually conditioned on specified launch dates and sometimes design-around commitments.
Limitations
Specific launch dates or settlement terms cannot be provided without the docket’s disposition text.
Is there a Paragraph IV challenge and what does it imply for exclusivity?
Short answer: The litigation caption and likely context indicate an Orange Book dispute consistent with Paragraph IV certification, but the exact certification type and the specific patents tied to it are not confirmed from the identifier alone.
Typical implications
- A Paragraph IV certification generally triggers statutory litigation timeframes and stay mechanics.
- The resulting FDA approval and marketing timing depend on litigation outcomes and any FDA exclusivity expiration (if applicable).
This can’t be mapped to statutory dates without the Orange Book patent list and FDA product identifiers.
What is the Orange Book status of the asserted patents in 1:17-cv-01637?
Short answer: Not determinable from the information provided.
What an Orange Book check would normally show
- RLD name
- NDA holder
- Patent numbers and listed claim types:
- composition/formulation
- method-of-use
- device/manufacturing (less common in classic ANDA disputes)
- Expiration dates and any pediatric exclusivity adjustments
Because the RLD and patent numbers are not identified, no Orange Book table can be produced.
Which companies are challenging Mayne’s product in this docket, and who are the patent holders?
Short answer: Defendant is Lupin Atlantis Holdings SA; plaintiff is Mayne Pharma International Pty Ltd. Patent holder(s) and co-plaintiffs/third parties are not determinable from the case identifier alone.
Why patent-holder mapping matters
In many litigations:
- The NDA holder is not always the assignee of all asserted patents.
- Licensing relationships may allocate enforcement rights, which affects settlement dynamics and downstream indemnity.
Key Takeaways
- Case: Mayne Pharma International Pty Ltd. v. Lupin Atlantis Holdings SA, 1:17-cv-01637.
- Nature: A federal pharmaceutical patent infringement action consistent with Hatch-Waxman/Orange Book dispute mechanics.
- Commercial effect: Likely impacted the timing of ANDA-driven generic market entry for the RLD tied to the asserted patent(s).
- Missing from identifier-only inputs: asserted patent numbers, RLD/drug identity, certification type, specific legal theories, claim construction outcomes, dispositive motions, final disposition, and any settlement terms.
- Actionable analysis constraint: Without case disposition text and patent list, the litigation can’t be tied to specific expiration dates, validity holdings, or entry/royalty terms.
FAQs
- What statutory basis typically underlies Mayne v. Lupin Atlantis type disputes (1:17-cv-01637)?
- Do Hatch-Waxman cases like 1:17-cv-01637 usually involve claim construction (Markman) hearings?
- How do settlements in ANDA patent cases usually determine generic launch dates and market-entry conditions?
- What claim types (formulation vs method-of-use) most commonly drive infringement outcomes in Orange Book litigations?
- How does a court’s validity ruling versus infringement-only ruling change downstream patent risk for the ANDA sponsor?
References (APA)
- Docket information for Mayne Pharma International Pty Ltd. v. Lupin Atlantis Holdings SA, 1:17-cv-01637 (U.S. District Court).
